Literature DB >> 8508013

Study of serum procollagen type III peptide in patients with hepatic cirrhosis from a clinical point of view.

F Díaz1, J Collazos, J Genollá.   

Abstract

N-terminal procollagen-III peptide (P-III-P) has been considered a marker of fibrogenesis and inflammatory activity of the liver. We measured the P-III-P serum levels in 83 cirrhotic patients fully characterized from a clinical and laboratory point of view. Cirrhotic patients had significantly higher P-III-P serum levels than controls (P < 0.0001). Of the cirrhotic patients 73.5% had increased P-III-P. A significant negative correlation was found between P-III-P and transaminases, and patients with normal values of alanine amino-transferase had higher P-III-P serum levels than those with increased values (P = 0.03). On the other hand, no significant association was found with portal hypertension, Child classes, or alcoholic liver disease. No one independent factor appears to be responsible for the increase in P-III-P. The measurement of serum P-III-P is of little if any use in the evaluation of cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508013     DOI: 10.1007/BF00186633

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  22 in total

1.  Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis.

Authors:  A J McCullough; W N Stassen; R H Wiesner; A J Czaja
Journal:  J Lab Clin Med       Date:  1987-01

2.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

3.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

Authors:  H Rohde; L Vargas; E Hahn; H Kalbfleisch; M Bruguera; R Timpl
Journal:  Eur J Clin Invest       Date:  1979-12       Impact factor: 4.686

4.  Is determination of serum N-terminal procollagen type III peptide (sPIIIP) a marker of hepatic fibrosis?

Authors:  C Surrenti; A Casini; S Milani; S Ambu; P Ceccatelli; A D'Agata
Journal:  Dig Dis Sci       Date:  1987-07       Impact factor: 3.199

5.  Prognostic value of Child-Turcotte criteria in medically treated cirrhosis.

Authors:  E Christensen; P Schlichting; L Fauerholdt; C Gluud; P K Andersen; E Juhl; H Poulsen; N Tygstrup
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

6.  Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity.

Authors:  A J McCullough; W N Stassen; R H Wiesner; A J Czaja
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

7.  Clinical significance of serum type-III procollagen aminopropeptide in hepatitis B virus-related liver diseases.

Authors:  T T Chang; H C Lin; S D Lee; Y T Tsai; F Y Lee; F S Jeng; J C Wu; P S Yeh; K J Lo
Journal:  Scand J Gastroenterol       Date:  1989-06       Impact factor: 2.423

8.  Serum procollagen III N-terminal peptide and laminin P1 fragment concentrations in alcoholic liver disease and primary biliary cirrhosis.

Authors:  R A van Zanten; R E van Leeuwen; J H Wilson
Journal:  Clin Chim Acta       Date:  1988-10-14       Impact factor: 3.786

9.  Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease.

Authors:  K Weigand; P Y Zaugg; A Frei; A Zimmermann
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

10.  The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease.

Authors:  A Frei; A Zimmermann; K Weigand
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.